VIENNA, Va., June 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that a new corporate presentation is available for review on the Company's website at http://www.cel-sci.com/investor_relations.html. The presentation includes information on CEL-SCI's plans to develop a vaccine to prevent and treat swine and other influenza viruses using its L.E.A.P.S.(TM) technology platform, provides details on its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell derived therapies and other biological products and includes a review of the science underlying Multikine(R), which the Company is preparing to commence a pivotal Phase III trial for the treatment of head and neck cancer.
CEL-SCI is developing products that empower immune defenses. Its lead product is Multikine(R) which is currently being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.
|SOURCE CEL-SCI Corporation|
Copyright©2009 PR Newswire.
All rights reserved